List of Excipients in Branded Drug PROLEUKIN

Proleukin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Proleukin is aldesleukin, a recombinant human interleukin-2 used for high-dose immunotherapy in metastatic renal cell carcinoma and metastatic melanoma. Its commercial formulation is a lyophilized, single-use vial containing aldesleukin with mannitol, sodium dodecyl sulfate, and phosphate salts. The principal excipient opportunities are improved protein stability, reduced aggregation, lower injection burden, room-temperature handling, and reformulation for outpatient or lower-dose immunotherapy.

The strongest near-term commercial opportunities are likely to come from differentiated IL-2 delivery systems and biosimilar or follow-on biologic products rather than from substituting a single inactive ingredient in the existing vial.

What is the Proleukin formulation?

Proleukin is supplied as a sterile, white-to-off-white lyophilized powder for intravenous infusion. Each vial contains 22 million International Units of aldesleukin, equivalent to approximately 1.3 mg of protein. The product is reconstituted with Sterile Water for Injection before dilution and administration.[1]

Formulation element	Role in Proleukin
Aldesleukin	Recombinant human interleukin-2 active ingredient
Mannitol	Bulking agent and lyophilization stabilizer
Sodium dodecyl sulfate	Surfactant and protein-solubilizing excipient
Sodium phosphate salts	Buffer system controlling formulation pH
Sterile Water for Injection	Reconstitution vehicle, supplied separately

The product is administered at high doses through an intensive inpatient regimen. The approved dosing schedule can require repeated intravenous infusions over several days, followed by a rest period and, where appropriate, another treatment cycle.[1]

Why does Proleukin require a specialized excipient system?

Aldesleukin is a protein with sensitivity to aggregation, adsorption, interfacial stress, temperature, and repeated handling. The formulation must preserve activity during manufacturing, freeze-drying, storage, reconstitution, dilution, and infusion.

Mannitol supports cake formation and provides a solid-state matrix during lyophilization. Phosphate salts maintain pH. Sodium dodecyl sulfate is unusual in many injectable protein products because it is a strong surfactant, but it can help maintain solubility and reduce certain forms of protein aggregation. Its use also creates a formulation constraint because surfactant concentration, infusion compatibility, container interaction, and local tolerability must be controlled.

What excipients are protected by Proleukin patents?

The original Proleukin formulation has limited practical exclusivity value because the product was first approved in the early 1990s and its principal regulatory and composition-of-matter exclusivities have expired. Proleukin is regulated as a biologic under a biologics license application rather than as a conventional small-molecule drug.

Publicly available product information identifies the excipients but does not establish that each excipient combination remains covered by an enforceable, unexpired patent. A commercial freedom-to-operate analysis would need to review issued patents, continuations, terminal disclaimers, prosecution histories, assignments, and litigation records across the United States and other target markets.

Does Proleukin have Orange Book-listed patents?

No. Proleukin is a biologic and is not typically evaluated through the small-molecule Orange Book patent-certification framework. Its relevant regulatory records are maintained through the FDA biologics framework, including the Purple Book and the product’s BLA record.[2]

For this reason:

• Orange Book patent listings are not the principal source of Proleukin exclusivity information.
• A generic drug Paragraph IV filing is not the normal pathway for a Proleukin competitor.
• A follow-on product would generally require a biosimilar or interchangeable biosimilar strategy under the Public Health Service Act, or an independent biologics license application.
• Formulation patents, manufacturing patents, device patents, and method-of-use patents may still create commercial barriers even after reference-product exclusivity has expired.

When did Proleukin lose exclusivity?

Proleukin’s core exclusivity period expired many years ago. The product’s first FDA approval dates were:

Milestone	Date
Initial FDA approval for metastatic renal cell carcinoma	1992
FDA approval for metastatic melanoma	1998
Reference-product exclusivity under modern biologics rules	Expired
Current competitive pathway	Biosimilar or independent biologic development

The exact expiration of individual historical patents depends on the patent family and jurisdiction. No current commercial strategy should assume that the absence of Orange Book listings means the absence of patent risk. Patent exposure may arise from newer formulations, manufacturing methods, delivery systems, combination regimens, or supplier-owned excipient technologies.

What commercial opportunities exist in Proleukin excipients?

The commercial opportunity is not limited to replacing mannitol, phosphate, or sodium dodecyl sulfate. The higher-value opportunity is to improve the total product profile while preserving or improving biological activity.

1. Improved lyophilized formulation

A competing formulation could seek to improve:

• Reconstitution time
• Cake appearance and mechanical integrity
• Residual moisture
• Protein recovery
• Aggregation profile
• Storage temperature
• Container closure performance
• Dilution stability
• Infusion compatibility

Potential excipient classes include nonionic surfactants, amino acids, sugars, polyols, and alternative buffers. Candidates must be screened against protein activity, particulates, oxidation, deamidation, adsorption, and container interaction.

Replacing sodium dodecyl sulfate with a milder nonionic surfactant could have commercial value if the alternative maintains aldesleukin potency and reduces regulatory or tolerability concerns. Such a change would likely require extensive comparability work because surfactant identity can affect protein conformation, aggregation pathways, and bioassay results.

2. Liquid or concentrated liquid formulation

A ready-to-use or refrigerated liquid product could reduce reconstitution steps and pharmacy preparation time. The technical barriers are substantial:

• Aldesleukin stability in solution
• Aggregation during refrigerated storage
• Oxidation and deamidation
• Loss to infusion bags and tubing
• Microbial control
• Container closure compatibility
• Shipping excursion performance

A liquid formulation with a longer shelf life could support outpatient administration and reduce pharmacy labor. The tradeoff is the possibility of greater cold-chain dependence and higher risk of degradation during distribution.

3. Room-temperature-stable product

A room-temperature-stable Proleukin alternative would have value in markets with limited cold-chain infrastructure and in hospital systems seeking simplified inventory management. Lyophilization remains the most plausible platform, but the excipient system would need to protect the protein during elevated-temperature excursions.

Commercial claims could focus on:

• Longer allowable room-temperature exposure
• Reduced cold-chain requirements
• Higher post-reconstitution stability
• Lower product waste
• Easier emergency stock management

These claims would need direct stability evidence and could support formulation or process patent claims.

4. Lower-dose IL-2 formulation

The commercial market has shifted toward engineered or modified IL-2 therapies designed to alter receptor selectivity and improve tolerability. A lower-dose aldesleukin product could target outpatient or combination use, but it would face clinical and regulatory challenges.

Potential product concepts include:

• More concentrated aldesleukin for smaller infusion volumes
• Subcutaneous delivery
• Shorter infusion schedules
• Combination use with checkpoint inhibitors
• Regimens designed to expand regulatory T cells
• Dose-reduced therapy for patients unable to tolerate high-dose IL-2

Excipient innovation could support these concepts through increased concentration, reduced injection volume, improved subcutaneous tolerability, or enhanced stability in prefilled delivery systems.

5. Device-compatible formulation

A prefilled syringe, cartridge, wearable infusor, or infusion-ready presentation could improve administration efficiency. Protein adsorption to device surfaces is a critical issue, particularly at low concentrations. Surfactants and container materials would need to be selected together.

A device-compatible Proleukin product could be protected through a combination of:

• Formulation claims
• Container closure claims
• Device claims
• Method-of-use claims
• Stability claims
• Administration protocol claims

This strategy could create a more defensible commercial product than an excipient substitution alone.

Which excipient changes are technically most attractive?

Opportunity	Commercial value	Technical difficulty	Patent potential
Replace sodium dodecyl sulfate	Medium to high	High	Medium to high
Improve mannitol-based lyophilization	Medium	Medium	Medium
Develop liquid formulation	High	Very high	High
Increase protein concentration	High	Very high	High
Enable subcutaneous delivery	High	Very high	High
Improve room-temperature stability	High	High	High
Change phosphate buffer system	Low to medium	Medium	Low to medium
Create infusion-ready presentation	Medium to high	High	High

The most attractive programs combine several improvements. A formulation that merely changes phosphate concentration would probably have limited commercial differentiation unless it produces measurable gains in stability, administration, or manufacturing yield.

What formulation patents could protect a Proleukin follow-on product?

A follow-on developer could pursue patent claims covering:

Composition claims

These may cover:

• Aldesleukin concentration ranges
• Specific surfactants
• Sugar or polyol combinations
• Buffer identity and pH
• Excipient-to-protein ratios
• Low-aggregate formulations
• Reduced particulate formulations

Process claims

Potential claims include:

• Controlled-rate freezing
• Annealing during lyophilization
• Specific primary and secondary drying conditions
• Reconstitution procedures
• Protein recovery methods
• Removal or reduction of aggregation
• Aseptic filling and lyophilization processes

Container and administration claims

These may cover:

• Vial materials
• Syringe or cartridge presentations
• Infusion-bag compatibility
• Low-binding tubing
• Reconstitution devices
• Administration at a defined concentration or rate

Method-of-use claims

Possible claims could target:

• Reduced-dose aldesleukin treatment
• Subcutaneous administration
• Combination with checkpoint inhibitors
• Treatment of specific patient populations
• Biomarker-selected patients
• Outpatient administration
• Reduced cytokine-mediated toxicity

Method-of-use claims would require clinical support and may face narrower enforceability than composition or manufacturing claims.

What is the biosimilar risk for Proleukin?

The biosimilar risk is real but commercially complex. Aldesleukin is a recombinant protein, making analytical comparability feasible in principle. A developer would need to establish similarity in structure, purity, potency, aggregation, post-translational characteristics, and functional activity.

The key barriers are clinical and commercial:

• High-dose IL-2 has a difficult tolerability profile.
• Administration is resource-intensive.
• The market is smaller than the markets for many antibody biologics.
• A biosimilar may need to compete against newer immuno-oncology products.
• Hospital purchasing may favor lower price, but clinical centers may require extensive operational validation.
• Interchangeability could require additional evidence and would not automatically eliminate administration barriers.

A biosimilar with the same high-dose regimen could be price-competitive but operationally unattractive. A product with a materially better formulation, presentation, or administration profile would likely have greater commercial potential.

Which companies could challenge Proleukin commercially?

Competitive pressure comes from several categories rather than from one direct manufacturer.

Established immuno-oncology companies

Companies developing next-generation IL-2 agonists and receptor-biased cytokines compete for the same treatment rationale. These products may offer more selective immune activation, improved pharmacokinetics, or combination use with checkpoint inhibitors.

Biosimilar developers

Large biologics manufacturers and contract development organizations could develop an aldesleukin biosimilar or follow-on product. The commercial case would depend on manufacturing cost, clinical positioning, supply reliability, and hospital contracting.

Specialty pharmaceutical companies

A specialty company could pursue a reformulated aldesleukin product for lower-dose, subcutaneous, or outpatient use. This strategy would likely require new clinical evidence rather than relying only on analytical comparability.

Excipient and delivery-platform companies

Excipient suppliers may participate through proprietary stabilizers, low-binding materials, lyophilization platforms, or prefilled delivery systems. Their value would come through licensing, formulation partnerships, or supply agreements.

What licensing opportunities exist around Proleukin formulation?

Licensing opportunities can be structured around four assets:

1. A proprietary excipient system that improves aldesleukin stability.
2. A lyophilization process that increases yield or shelf life.
3. A delivery device that reduces preparation and administration burden.
4. A clinical formulation that supports lower-dose or outpatient treatment.

A platform owner could license technology to a biosimilar developer, specialty pharmaceutical company, or contract manufacturer. The most valuable deal structure would likely combine an upfront payment, development milestones, commercial royalties, and supply rights for a proprietary excipient or device component.

A formulation license should address ownership of improvements, regulatory responsibility, manufacturing transfer, analytical methods, supply continuity, and rights to combination products. It should also distinguish between the formulation patent, the biologic manufacturing process, and any device patent.

What litigation and Paragraph IV risks apply?

A conventional Paragraph IV challenge is not the expected route for Proleukin because it is a biologic rather than a small-molecule drug. Potential disputes would instead involve:

• Biosimilar patent-exchange procedures
• BLA or 351(k) regulatory disputes
• Patent infringement claims
• Trade-secret disputes involving manufacturing
• Contract disputes with contract manufacturers
• Device or container patents
• Method-of-use patent enforcement

A follow-on developer should conduct a global patent landscape covering aldesleukin sequence patents, expression systems, refolding, purification, formulation, lyophilization, containers, administration devices, and combination therapy. Manufacturing know-how may be more important than expired composition patents.

How does Proleukin compare with newer IL-2 products?

Attribute	Proleukin	Next-generation IL-2 agonists
Active agent	Native recombinant aldesleukin	Often engineered or receptor-biased IL-2
Main use	High-dose immunotherapy	Often combination immuno-oncology or immune modulation
Administration burden	High	Product-dependent
Formulation opportunity	Strong	Often already built into development program
Biosimilar potential	Feasible in principle	Usually limited by newer patents
Commercial differentiation	Cost, stability, convenience	Selectivity, tolerability, pharmacokinetics
Patent position	Core rights largely mature	Often stronger and more current

Proleukin’s main weakness is its administration burden and toxicity profile. Its main commercial advantage is clinical familiarity, established regulatory status, and the possibility of a lower-cost follow-on product.

What generic launch scenarios exist?

Scenario 1: Low-cost biosimilar

A biosimilar matches the existing lyophilized vial and high-dose regimen. It competes mainly on price and supply reliability. This is the lowest-risk development strategy but may produce limited market expansion.

Scenario 2: Improved lyophilized product

The product retains the same active ingredient but improves reconstitution, stability, or storage. It may obtain formulation patents and command a modest premium.

Scenario 3: Liquid or concentrated product

The product reduces preparation steps and may support outpatient use. Development risk is higher, but the product could achieve stronger differentiation.

Scenario 4: Subcutaneous or lower-dose product

This strategy targets convenience and potentially broader use. It requires substantial clinical development and may encounter method-of-use and device competition.

Scenario 5: Combination immunotherapy product

Aldesleukin is positioned with a checkpoint inhibitor or another immune therapy. The commercial upside is larger, but clinical, regulatory, and patent complexity increase.

What is the revenue exposure?

The relevant revenue opportunity is determined by the size of the remaining high-dose IL-2 market, not by the broader immuno-oncology market. A follow-on product would face a mature product category with limited treatment volume, intensive administration requirements, and competition from newer immunotherapies.

Revenue upside increases materially if formulation innovation expands use beyond the traditional inpatient population. The most valuable commercial claims would be:

• Reduced hospitalization
• Lower treatment-center labor
• Fewer discarded vials
• Longer shelf life
• Easier distribution
• Lower infusion volume
• Improved patient eligibility
• Use in combination regimens

A pure excipient substitution without a measurable clinical or operational benefit is unlikely to support substantial pricing power.

How strong is the Proleukin patent estate?

The legacy Proleukin patent estate is likely weak relative to newer engineered IL-2 products because the active ingredient and original formulation date from an early biologics era. The more relevant barriers are regulatory comparability, manufacturing know-how, clinical positioning, and any later patents covering improved formulations or administration methods.

Patent category	Expected strategic importance
Original aldesleukin composition	Low because of age
Original formulation	Low to medium, subject to family review
Lyophilization process	Medium
Liquid or concentrated formulation	High if claims are technically narrow and enabled
Delivery device	Medium to high
Combination therapy	High where clinically supported
Manufacturing know-how	High even without broad patent protection
Excipient supplier IP	Medium to high

Key Takeaways

• Proleukin contains aldesleukin with mannitol, sodium dodecyl sulfate, and phosphate salts in a lyophilized vial.[1]
• The principal opportunity is a differentiated follow-on biologic, not a simple excipient replacement.
• Liquid, concentrated, room-temperature-stable, and device-compatible formulations offer the strongest commercial potential.
• Proleukin is not an Orange Book product in the conventional small-molecule sense.
• Paragraph IV litigation is not the expected competitive pathway; biosimilar and biologics patent disputes are more relevant.
• A follow-on product must address both protein stability and the operational burden of high-dose IL-2 administration.
• Manufacturing know-how, formulation patents, device rights, and clinical method-of-use claims may provide stronger protection than legacy composition patents.
• Commercial value depends on expanding access, reducing hospital resource use, or enabling a lower-dose regimen.

FAQs About Proleukin Excipient and Formulation Strategy

What is the most important Proleukin excipient?

Mannitol is important for lyophilized cake formation and solid-state stability, while sodium dodecyl sulfate helps manage protein solubility and aggregation. The excipients function as a system rather than as independent ingredients.

Can sodium dodecyl sulfate be removed from Proleukin?

It may be possible to replace it with another surfactant, but the alternative must preserve aldesleukin potency, solubility, aggregation profile, and infusion compatibility. The change would require extensive analytical and regulatory comparability work.

Can Proleukin be reformulated for subcutaneous injection?

A subcutaneous product could be developed, but it would require evidence on concentration, local tolerability, injection volume, pharmacokinetics, immunogenicity, and clinical efficacy. The product could also require a new device and method-of-use strategy.

Is a Proleukin biosimilar likely to receive automatic interchangeability?

Interchangeability would depend on the applicable FDA pathway and the supporting evidence submitted by the sponsor. Biosimilarity alone does not guarantee interchangeable status.

Which Proleukin formulation opportunity has the highest licensing value?

A stable, concentrated, low-volume formulation that supports outpatient or subcutaneous administration would likely have greater licensing value than a buffer-only change because it can create clinical and operational differentiation.

References

1. U.S. Food and Drug Administration. (2023). Proleukin (aldesleukin) prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2020). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/

4. National Cancer Institute. (2024). Aldesleukin. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aldesleukin